Pembrolizumab (Keytruda) is marketed for the treatment of hepatocellular carcinoma in USA and Europe and is an antineoplastic immunomodulating molecule that antagonist mechanism on Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.